Palifermin
Palifermin (Kepivance) is a growth factor injected for three days before and after high-dose chemotherapy and stem cell rescue to reduce the severe mouth ulcers (mucositis) that this treatment causes in people with blood cancers.
Overview
Palifermin was approved by the FDA in December 2004 to decrease the incidence and duration of severe oral mucositis in patients with haematological malignancies receiving myelotoxic therapy with autologous stem cell support, when the regimen is expected to cause WHO grade 3 or worse mucositis in most patients; in the pivotal randomised trial of 212 patients receiving total body irradiation-based conditioning, grade 3 to 4 mucositis fell from 98% to 63% and its duration from 9 to 3 days. The EU authorised Kepivance in 2005. Its safety in non-haematological malignancies is not established because KGF receptors are present on many epithelial tumours, and it is not given within 24 hours of chemotherapy. Rash, tongue thickening and taste change are the usual effects. Marketed by Sobi.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2004 | Reduction of severe oral mucositis in haematological malignancies with myelotoxic therapy and autologous stem cell support |
| EU | 2005 | Same (Kepivance) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Palifermin" OR ABSTRACT:"Palifermin" OR TITLE:"Kepivance" OR ABSTRACT:"Kepivance" OR TITLE:"Recombinant keratinocyte growth factor" OR ABSTRACT:"Recombinant keratinocyte growth factor" OR TITLE:"rHuKGF" OR ABSTRACT:"rHuKGF") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Palifermin, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductPlerixafor
Shares Autologous stem cell transplant (high-dose therapy), Multiple myeloma, Diffuse large B-cell lymphoma and the tags nci-list, supportive.
- ProductDefibrotide
Shares Autologous stem cell transplant (high-dose therapy) and the tags nci-list, supportive.
- ProductRasburicase
Shares Diffuse large B-cell lymphoma and the tags nci-list, supportive.
- ProductDenosumab
Shares Multiple myeloma and the tags nci-list, supportive.
- ProductDexamethasone
Shares Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and the tags nci-list, supportive.
- ProductCarmustine
Shares Autologous stem cell transplant (high-dose therapy), Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and the tag nci-list.
- ProductAmifostine
Shares the tags nci-list, supportive.
- ProductAprepitant (and fosaprepitant)
Shares the tags nci-list, supportive.